Today’s podcast features discussions from the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) which took place in Nice, France. You will hear updates on the use of CAR T-cell therapy in non-Hodgkin lymphoma (NHL) from experts Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children’s National Health System, Washington, DC, Stephen Schuster, MD, University of Pennsylvania, Philadelphia, PA, and Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX. They discuss where CAR-T fits into the treatment landscape, managing toxicities, and the potential of allogeneic CAR-T products.

You will also hear from Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, and Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, who share insights into the use of bispecific antibodies in the treatment of NHL. Their discussion focuses on comparisons between CAR-T and bispecifics and the unique challenges of using bispecific antibodies, including mitigating toxicities. They also mention exciting combination approaches with antibody-drug conjugates and co-stimulatory agents.

The post CAR T-cells and bispecific antibodies in the treatment of NHL: updates from iwNHL 2024 appeared first on VJHemOnc.